文献速递肝病

慢性丁型肝炎纤维化分期的无创标志物

Noninvasive markers for staging fibrosis in chronic delta hepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-04

该研究评估了FIB-4、AST/ALT比值、AAR、API、APRI和Hui评分在慢性HDV感染中检测进展性纤维化(Ishak≥4)和肝硬化(Ishak=6)的能力,并与HBV、HCV患者比较。共纳入1003例受试者(HCV=701、HBV=240、HDV=62),HDV患者中FIB-4表现最佳,但血清纤维化标志物在HDV中的准确性低于HBV和HCV。

要点

  • HDV患者FIB-4检测进展性纤维化的AUROC为0.70(95%CI 0.55-0.84),检测肝硬化为0.83(95%CI 0.69-0.97)。
  • FIB-4在所有病毒队列中检测进展性纤维化和肝硬化表现最佳。
  • 血清纤维化标志物在慢性HDV感染中的准确性低于HBV和HCV患者。

核心结论

  • 血清纤维化标志物在慢性HDV感染患者中的性能准确性低于HBV和HCV患者,应探索其他无创纤维化标志物以辅助这些患者的管理。

研究设计与样本

  • 评估HBV、HCV和HDV患者的临床与组织学实验室数据并计算血清纤维化标志物,比较各病毒感染间标志物检测进展性纤维化(Ishak≥4)和肝硬化(Ishak=6)的能力。
  • 共纳入1003例受试者(HCV=701、HBV=240、HDV=62),平均年龄46±11岁,66%为男性。

主要发现

  • HDV患者ALT和AST高于HCV、血小板低于HBV和HCV,组织学上Ishak≥4和坏死性炎症比例最高。
  • HDV中检测进展性纤维化的AUROC:FIB-4=0.70(95%CI 0.55-0.84)、API=0.69(95%CI 0.55-0.82)、APRI=0.68(95%CI 0.54-0.82)、Hui评分=0.63(95%CI 0.49-0.78)、AAR=0.63(95%CI 0.48-0.77)。
  • HDV中检测肝硬化的AUROC:FIB-4=0.83(95%CI 0.69-0.97)、API=0.80(95%CI 0.66-0.95)、APRI=0.75(95%CI 0.61-0.89)、Hui评分=0.70(95%CI 0.49-0.91)、AAR=0.70(95%CI 0.48-0.93)。
  • 调整已发表的截断值后,HDV中FIB-4检测进展性纤维化和APRI检测肝硬化仅有边际改善。

临床怎么用

  • 作者认为应探索其他无创纤维化标志物以辅助慢性HDV感染患者的管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV). AIM: To evaluate the utility of serum fibrosis markers [fibrosis-4 score (FIB-4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, aspartate aminotransferase ratio (AAR), age-platelet index (API), AST-to-platelet-ratio-index (APRI) and Hui score] in HDV infection. METHODS: Clinical and histologic laboratory data from HBV, HCV and HDV patients were evaluated and serum fibrosis markers were calculated. The ability of fibrosis markers to detect advanced fibrosis (Ishak ≥4) and cirrhosis (Ishak = 6) were evaluated and compared between viral infections. RESULTS: A total of 1003 subjects (HCV = 701, HBV = 240 and HDV = 62) with mean age of 46 ± 11 and 66% male were evaluated. HDV subjects had higher ALT and AST than HCV and lower platelets than both HBV and HCV. Histologically, HDV had the greatest percentage of Ishak ≥4 and necroinflammation. FIB-4 performed best in detecting advanced fibrosis and cirrhosis in all viral cohorts. In HDV, area under the receiver operator curve (AUROC) 95% confidence intervals for detecting advanced fibrosis were: FIB-4 = 0.70 (0.55-0.84), API = 0.69 (0.55-0.82), APRI = 0.68 (0.54-0.82), Hui score = 0.63 (0.49-0.78), AAR = 0.63 (0.48-0.77). The AUROC for detecting cirrhosis in HDV were: FIB-4 = 0.83 (0.69-0.97), API = 0.80 (0.66-0.95), APRI = 0.75 (0.61-0.89), Hui score = 0.70 (0.49-0.91) and AAR = 0.70 (0.48-0.93). Adjustment of published cut-offs led to marginal improvements in FIB4 for advanced fibrosis and of APRI for cirrhosis in HDV. CONCLUSIONS: Serum fibrosis markers have lower performance accuracy in chronic HDV infected patients compared to HBV and HCV patients. Other noninvasive fibrosis markers should be explored to assist in the management of these patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Takyar V, Surana P, Kleiner DE, et al. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2016. PMID: 27813124. doi:10.1111/apt.13834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。